Cargando…

Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non–small‐cell lung cancer

The clinical outcome of resectable non–small‐cell lung cancer (NSCLC) patients receiving neoadjuvant chemoimmunotherapy is good but varies greatly. In addition, the pathological response after neoadjuvant chemoimmunotherapy is significantly associated with survival outcomes. The aim of this retrospe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Rui, Zhang, Yimin, Wang, Tianhu, Xiao, Hualiang, Luo, Zhilin, Shen, Cheng, Li, Jianghua, Zhao, Chenglong, Li, Li, Zhu, Mengxiao, Du, Haiwei, Tang, Huan, Ma, Zheng, Wang, Yubo, He, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236616/ https://www.ncbi.nlm.nih.gov/pubmed/36880750 http://dx.doi.org/10.1111/cas.15778

Ejemplares similares

Pathologic responses to neoadjuvant chemoimmunotherapy in primary limited‐stage small‐cell lung cancer
por: Lu, Meng, et al.
Publicado: (2022)

The rational application of liquid biopsy based on next‐generation sequencing in advanced non‐small cell lung cancer
por: Zhao, Chenglong, et al.
Publicado: (2022)

Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer
por: Hu, Yan, et al.
Publicado: (2021)

Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2021)

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2022)

Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: A multicentre study
por: She, Yunlang, et al.
Publicado: (2022)

Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis
por: Jiang, Juan, et al.
Publicado: (2022)

Predicting pathological response to neoadjuvant or conversion chemoimmunotherapy in stage IB–III non‐small cell lung cancer patients using radiomic features
por: Yang, Nong, et al.
Publicado: (2023)

Pattern of tumor regression after neoadjuvant chemoimmunotherapy for esophageal squamous cell carcinoma
por: Li, Bin, et al.
Publicado: (2023)

A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer
por: Liu, Wei, et al.
Publicado: (2022)

Sleeve lobectomy after neoadjuvant chemoimmunotherapy/chemotherapy for local advanced non-small cell lung cancer
por: Liang, Hengrui, et al.
Publicado: (2021)

Sleeve resection after neoadjuvant chemoimmunotherapy in the treatment of locally advanced non-small cell lung cancer
por: Dai, Jie, et al.
Publicado: (2022)

A real‐world comparison between neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable non‐small cell lung cancer
por: Zhang, Baihua, et al.
Publicado: (2022)

Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer
por: Sun, Xiaoyan, et al.
Publicado: (2022)

Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Neoadjuvant chemoimmunotherapy cycle number selection for non-small cell lung cancer and clinical outcomes: a real-world analysis
por: Zhang, Baihua, et al.
Publicado: (2023)

Surgical perspective in neoadjuvant chemoimmunotherapy for stage II–III non‐small cell lung cancer
por: Hong, Tao, et al.
Publicado: (2021)

Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer
por: Chen, Hualin, et al.
Publicado: (2022)

Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in a Patient With Metastatic Intrahepatic Cholangiocarcinoma With High Tumor Mutational Burden
por: Abudalou, Mohammad, et al.
Publicado: (2021)

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2021)

Tanshinone IIA Reverses Gefitinib-Resistance In Human Non-Small-Cell Lung Cancer Via Regulation Of VEGFR/Akt Pathway
por: Wang, Rui, et al.
Publicado: (2019)

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial
por: Laza‐Briviesca, Raquel, et al.
Publicado: (2021)

Safety and feasibility of robotic-assisted thoracic surgery after neoadjuvant chemoimmunotherapy in non-small cell lung cancer
por: Zeng, Jun, et al.
Publicado: (2023)

Injectable pH-responsive hydrogel for combinatorial chemoimmunotherapy tailored to the tumor microenvironment
por: Gu, Jun, et al.
Publicado: (2022)

Inhibition of IDH3α Enhanced the Efficacy of Chemoimmunotherapy by Regulating Acidic Tumor Microenvironments
por: Zhang, Lingling, et al.
Publicado: (2023)

Organ preservation strategies after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a multicenter retrospective cohort study
por: Hui, Bengang, et al.
Publicado: (2023)

First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments
por: Nie, Naifu, et al.
Publicado: (2022)

Erratum: Safety and feasibility of robotic-assisted thoracic surgery after neoadjuvant chemoimmunotherapy in non-small cell lung cancer
Publicado: (2023)

Neoadjuvant immunotherapy versus chemoimmunotherapy in non-small cell lung cancer: A protocol for systematic review and meta-analysis
por: Zhu, Qunying, et al.
Publicado: (2023)

Perioperative Outcomes of Video-Assisted Thoracoscopic Surgery Versus Open Thoracotomy After Neoadjuvant Chemoimmunotherapy in Resectable NSCLC
por: Zhang, Baihua, et al.
Publicado: (2022)

Predictive value of early kinetics of ctDNA combined with cfDNA and serum CEA for EGFR‐TKI treatment in advanced non‐small cell lung cancer
por: Zheng, Jie, et al.
Publicado: (2022)

Intratumoral CD103(+)CD8(+) T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma
por: Ren, Siqi, et al.
Publicado: (2023)

Resistance to chemoimmunotherapy in non-small-cell lung cancer
por: Hochmair, Maximilian Johannes
Publicado: (2020)

Watershed analysis in wedge resection of pulmonary pure ground-glass nodules hardly localized by CT-guided puncture
por: Luo, Zhilin, et al.
Publicado: (2023)

Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy
por: Wang, Tianqi, et al.
Publicado: (2021)

Robotic-assisted thoracic surgery following neoadjuvant chemoimmunotherapy in patients with stage III non-small cell lung cancer: A real-world prospective cohort study
por: Gao, Yang, et al.
Publicado: (2022)

Neoadjuvant programmed cell death protein 1 inhibitors combined with chemotherapy in resectable non-small cell lung cancer: an open-label, multicenter, single-arm study
por: Duan, Hongtao, et al.
Publicado: (2021)

Epidemiological Evidence Between Variants in Matrix Metalloproteinases-2, -7, and -9 and Cancer Risk
por: Huang, Chenglu, et al.
Publicado: (2022)

Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Neoadjuvant chemoimmunotherapy as a potential therapeutic option in NSCLC UICC stage IIIA with multilevel N2 disease
por: Menghesha, Hruy, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5894iep4knbp62fc6bufob1fkh